1. Home
  2. FHI vs SRRK Comparison

FHI vs SRRK Comparison

Compare FHI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FHI
  • SRRK
  • Stock Information
  • Founded
  • FHI 1955
  • SRRK 2012
  • Country
  • FHI United States
  • SRRK United States
  • Employees
  • FHI N/A
  • SRRK N/A
  • Industry
  • FHI Investment Managers
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FHI Finance
  • SRRK Health Care
  • Exchange
  • FHI Nasdaq
  • SRRK Nasdaq
  • Market Cap
  • FHI 3.1B
  • SRRK 3.1B
  • IPO Year
  • FHI N/A
  • SRRK 2018
  • Fundamental
  • Price
  • FHI $42.74
  • SRRK $31.32
  • Analyst Decision
  • FHI Hold
  • SRRK Strong Buy
  • Analyst Count
  • FHI 6
  • SRRK 6
  • Target Price
  • FHI $42.33
  • SRRK $42.17
  • AVG Volume (30 Days)
  • FHI 850.3K
  • SRRK 1.4M
  • Earning Date
  • FHI 04-24-2025
  • SRRK 05-14-2025
  • Dividend Yield
  • FHI 3.18%
  • SRRK N/A
  • EPS Growth
  • FHI 2.09
  • SRRK N/A
  • EPS
  • FHI 3.58
  • SRRK N/A
  • Revenue
  • FHI $1,659,262,000.00
  • SRRK N/A
  • Revenue This Year
  • FHI $6.24
  • SRRK N/A
  • Revenue Next Year
  • FHI $3.75
  • SRRK $601.05
  • P/E Ratio
  • FHI $11.95
  • SRRK N/A
  • Revenue Growth
  • FHI 2.19
  • SRRK N/A
  • 52 Week Low
  • FHI $31.24
  • SRRK $6.76
  • 52 Week High
  • FHI $43.92
  • SRRK $46.98
  • Technical
  • Relative Strength Index (RSI)
  • FHI 68.79
  • SRRK 49.35
  • Support Level
  • FHI $41.04
  • SRRK $28.76
  • Resistance Level
  • FHI $42.92
  • SRRK $33.48
  • Average True Range (ATR)
  • FHI 0.91
  • SRRK 1.66
  • MACD
  • FHI 0.42
  • SRRK -0.00
  • Stochastic Oscillator
  • FHI 97.15
  • SRRK 43.66

About FHI Federated Hermes Inc.

ederated provides asset management services for institutional and individual investors. The company had $757.6 billion in managed assets at the end of December 2023, composed of equity (10%), multi-asset (less than 1%), fixed-income (13%), alternative (3%), and money market (74%) funds. That said, the firm's cash-management operations are expected to generate around 46% of Federated's revenue this year, compared with 29%, 13%, and 11%, respectively, for the firm's equity, fixed-income, and alternatives/multi-asset operations. From a channel perspective, the company's products are distributed via trust banks, wealth managers and retail broker/dealers (63% of AUM), institutional investors (28%), and international clients (9%).

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Share on Social Networks: